LONDON, Aug. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will be participating in the following, upcoming investor conferences:

• Dr. Christian Itin, chief executive officer, will present at the Wells Fargo 13th Annual Healthcare Conference on Wednesday, September 5, at 9:40 a.m. ET in Boston, MA. A webcast of the presentation will be available on the investor relations section of the company's website: https://www.autolus.com
• Christopher Vann, chief operating officer, will present at the H.C. Wainwright 20^th Annual Global Investment Conference on Thursday, September 6, at 3:50 p.m. ET in New York, NY
• Dr. Itin will present at the 16^th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, at 3:50 p.m. ET in New York, NY. A webcast of the company's fireside chat will be available on the investor relations section of Autolus' website: https://www.autolus.com

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

View original content with multimedia:http://www.prnewswire.com/news-releases/autolus-to-present-at-upcoming-investor-conferences-300704778.html

SOURCE Autolus Therapeutics plc